Recruiting

Study on Immunotherapy with Atezolizumab, Tiragolumab, and Ipilimumab for Patients with Advanced Triple Negative Breast Cancer

Registered drugNo placebo

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying new treatment strategies for patients with advanced Triple Negative Breast Cancer (TNBC). TNBC is a type of breast cancer that does not have any of the three common receptors known to fuel most breast cancer growth: estrogen, progesterone, and the HER2 protein. This study will explore the effectiveness and safety of novel immunotherapy treatments for patients with advanced stages of this disease, which may include cases where the cancer has spread to other parts of the body or cannot be surgically removed.

The trial will involve the use of several medications, including Tecentriq (atezolizumab), Tiragolumab, and YERVOY (ipilimumab). These medications are given as a solution through an intravenous infusion, which means they are administered directly into the bloodstream through a vein. The study will also include a placebo group to help compare the effects of the treatments. The main goal is to determine how well these treatments work and how safe they are for patients with advanced TNBC.

Participants in the study will receive treatment over a period of up to 24 months. During this time, they will be monitored for any changes in their condition and any side effects they may experience. The study aims to see if these new treatments can help control the cancer and improve the quality of life for patients with advanced TNBC. The trial will also assess how long patients can live without the disease getting worse and overall survival rates. This research is part of ongoing efforts to find better treatment options for people with this challenging form of breast cancer.

The research process

The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.

Step 1
Initial visit and consent
Upon joining the study, you will have an initial visit where the study team will explain the trial in detail. You will be asked to sign an informed consent form, which confirms your understanding and agreement to participate in the trial.
Step 2
Baseline assessments
Before starting treatment, several assessments will be conducted to establish your baseline health status. These may include blood tests, imaging scans, and a biopsy of a metastatic lesion if accessible.
Step 3
Treatment initiation
You will begin receiving the study medications through intravenous infusion. The medications include atezolizumab, tiragolumab, and ipilimumab. The specific dosage and frequency will be determined by the study protocol and your healthcare team.
Step 4
Ongoing treatment and monitoring
Throughout the trial, you will continue to receive the study medications as per the schedule. Regular monitoring will be conducted to assess your response to the treatment and to check for any side effects. This may involve additional blood tests, imaging scans, and possibly more biopsies.
Step 5
12-week evaluation
After 12 weeks of treatment, a comprehensive evaluation will be performed to determine the progression-free survival rate. This involves assessing whether the cancer has progressed or if there have been any adverse events.
Step 6
Follow-up and final assessments
At the end of the treatment period or if you decide to leave the study, final assessments will be conducted. These will help determine the overall survival and clinical benefit of the treatment.

Who can join the trial?

19 criteria

Must have **advanced triple negative breast cancer (TNBC)**, which means the cancer has spread or cannot be removed by surgery.
Must have a confirmed diagnosis showing **estrogen receptor (ER)** and **HER2 negativity** on a biopsy of the cancer that has spread.
Must have certain blood test results within specific limits, such as:
- **Bilirubin** less than 1.5 times the normal limit (except for those with Gilbert Syndrome, where it can be less than 3 times the normal limit).
- **Alkaline phosphatase** less than 2.5 times the normal limit (or less than 5 times if cancer has spread to the liver, and less than 7 times if it has spread to the bones).
- **Transaminases (ASAT/ALAT)** less than 3 times the normal limit (or less than 5 times if cancer has spread to the liver).
- **LDH** less than 2 times the normal limit.
- Must have a **creatinine clearance** (a measure of kidney function) greater than 40 mL/min.
- Must have signed an **informed consent**, which means agreeing to participate after understanding the study details.
- Must have **PD-L1 negative disease** or have been previously treated with anti-PD(L)1 therapy.
- Must have a cancer lesion that can be biopsied (sampled) for study purposes.
- Must be **18 years or older**.
- Must have a **WHO performance status** of 0 or 1, indicating good physical health.
- Must have had a maximum of three lines of chemotherapy for cancer that has spread, with evidence of disease progression.
- Must have **measurable or evaluable disease** according to specific criteria (RECIST 1.1).
- Must have a **disease-free interval** longer than 1 year, unless the cancer was metastatic from the start or no prior chemotherapy was given.
- Must have certain blood cell counts within specific limits, such as:
  - **White blood cells (WBC)** at least 2.0 x 10⁹/L.
  - **Absolute neutrophil count (ANC)** at least 1.5 x 10⁹/L without recent use of growth factors.
  - **Platelets** at least 100 x 10⁹/L.
  - **Hemoglobin** at least 5.0 mmol/L.

Who cannot join the trial?

3 criteria

Patients with **advanced TNBC** (Triple-Negative Breast Cancer) that cannot be surgically removed or has spread to other parts of the body cannot participate.
Patients who are not within the specified age range for the study cannot participate.
Patients who are part of a vulnerable population, such as those unable to give consent, cannot participate.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Recruiting

Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Immunotherapy is a type of treatment that helps your body's immune system fight cancer. In this trial, the focus is on using new strategies to boost the immune system's ability to target and destroy cancer cells in patients with advanced triple-negative breast cancer. This approach aims to enhance the body's natural defenses to improve the effectiveness of cancer treatment.

What is already known about the treatment

Novel Immunotherapy Strategies – This medication is administered as part of a clinical trial for patients with advanced Triple Negative Breast Cancer (TNBC), specifically those with irresectable recurrent or metastatic disease. The current status of this treatment in medical literature is experimental, as it is being evaluated for its effectiveness and safety in this trial. The main therapeutic indication is to treat advanced TNBC by using innovative approaches to modulate the immune system. At the molecular level, the mechanism of action involves enhancing the body's immune response to target and destroy cancer cells. This medication falls under the pharmacological classification of immunotherapy, which aims to boost the immune system's ability to fight cancer.

Investigated diseases

Triple-Negative Breast Cancer (TNBC) – Triple-Negative Breast Cancer is a type of breast cancer that lacks three common receptors known to fuel most breast cancer growth: estrogen, progesterone, and the HER-2/neu gene. This absence makes it more challenging to treat, as hormone therapies and drugs targeting HER-2 are ineffective. TNBC tends to be more aggressive and has a higher likelihood of spreading and recurring compared to other breast cancer types. It often progresses rapidly, with symptoms including a lump or mass in the breast, changes in breast shape, and skin dimpling. The disease can advance to an irresectable recurrent stage, where the cancer returns and cannot be surgically removed, or to a metastatic stage, where it spreads to other parts of the body. Monitoring and managing the disease focus on slowing progression and managing symptoms.